A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.

Key Points

• This research aims to evaluate the immunogenicity and tolerance of novel SARS-CoV-2 mRNA vaccine candidates.
• Developed two candidate vaccines using mRNA technology and virus-like particles.
• Conducted a phase 1 randomized clinical trial with adult participants.
• Compared the immunogenicity and tolerance of the new vaccines against a licensed mRNA vaccine.
• AZD6563 demonstrated similar immunogenicity to BNT162b2 at one third the dosage (10 μg versus 30 μg).
• Both candidate vaccines were well tolerated compared to the licensed vaccine.